Skip to main content
Erschienen in:

09.01.2020 | Brachytherapie | Schwerpunkt: Lebertumoren

Lokoregionäre und lokal ablative Therapien von Lebertumoren

verfasst von: PD Dr. med. J. B. Hinrichs, F. K. Wacker

Erschienen in: Die Innere Medizin | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die interventionelle Radiologie bietet eine Vielzahl von lokoregionären und lokal ablativen Therapieverfahren zur Behandlung von Lebertumoren. Diese können als eigenständige minimal-invasive Therapien, in Kombination mit anderen Therapien und je nach Tumorstadium kurativ oder palliativ angewendet werden. Im vorliegenden Übersichtsbeitrag stellen wir die verschiedenen Techniken vor und beschreiben den klinischen Stellenwert in der Therapie des hepatozellulären Karzinoms und intrahepatischen cholangiozellulären Karzinoms.
Literatur
1.
Zurück zum Zitat Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T et al (2018) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv238–iv255CrossRef Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T et al (2018) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv238–iv255CrossRef
2.
Zurück zum Zitat Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W et al (2013) Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 51:1269–1326CrossRef Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W et al (2013) Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 51:1269–1326CrossRef
3.
Zurück zum Zitat Spolverato G, Vitale A, Ejaz A, Kim Y, Maithel SK, Cosgrove DP et al (2015) The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. World J Surg 39:1474–1484CrossRef Spolverato G, Vitale A, Ejaz A, Kim Y, Maithel SK, Cosgrove DP et al (2015) The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. World J Surg 39:1474–1484CrossRef
4.
Zurück zum Zitat Uhlig J, Sellers CM, Stein SM, Kim HS (2019) Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol 29:2679–2689CrossRef Uhlig J, Sellers CM, Stein SM, Kim HS (2019) Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol 29:2679–2689CrossRef
5.
Zurück zum Zitat Chen S, Peng Z, Lin M, Chen Z, Hu W, Xie X et al (2018) Combined percutaneous radiofrequency ablation and ethanol injection versus hepatic resection for 2.1–5.0 cm solitary hepatocellular carcinoma: a retrospective comparative multicentre study. Eur Radiol 28:3651–3660CrossRef Chen S, Peng Z, Lin M, Chen Z, Hu W, Xie X et al (2018) Combined percutaneous radiofrequency ablation and ethanol injection versus hepatic resection for 2.1–5.0 cm solitary hepatocellular carcinoma: a retrospective comparative multicentre study. Eur Radiol 28:3651–3660CrossRef
6.
Zurück zum Zitat Shady W, Petre EN, Do KG, Gonen M, Yarmohammadi H, Brown KT et al (2018) Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol 29:268–275.e1CrossRef Shady W, Petre EN, Do KG, Gonen M, Yarmohammadi H, Brown KT et al (2018) Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol 29:268–275.e1CrossRef
7.
Zurück zum Zitat Vogl TJ, Nour-Eldin N‑EA, Hammerstingl RM, Panahi B, Naguib NNN (2017) Microwave ablation (MWA): basics, technique and results in primary and metastatic liver neoplasms - review article. Fortschr Röntgenstr 189:1055–1066CrossRef Vogl TJ, Nour-Eldin N‑EA, Hammerstingl RM, Panahi B, Naguib NNN (2017) Microwave ablation (MWA): basics, technique and results in primary and metastatic liver neoplasms - review article. Fortschr Röntgenstr 189:1055–1066CrossRef
8.
Zurück zum Zitat Ringe KI, Lutat C, Rieder C, Schenk A, Wacker F, Raatschen H‑J (2015) Experimental evaluation of the heat sink effect in hepatic microwave ablation. PLoS ONE 10:e134301CrossRef Ringe KI, Lutat C, Rieder C, Schenk A, Wacker F, Raatschen H‑J (2015) Experimental evaluation of the heat sink effect in hepatic microwave ablation. PLoS ONE 10:e134301CrossRef
9.
Zurück zum Zitat Qian G‑J, Wang N, Shen Q, Sheng YH, Zhao J‑Q, Kuang M et al (2012) Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. Eur Radiol 22:1983–1990CrossRef Qian G‑J, Wang N, Shen Q, Sheng YH, Zhao J‑Q, Kuang M et al (2012) Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. Eur Radiol 22:1983–1990CrossRef
10.
Zurück zum Zitat Huo YR, Eslick GD (2015) Microwave ablation compared to radiofrequency ablation for hepatic lesions: a meta-analysis. J Vasc Interv Radiol 26:1139–1146.e2CrossRef Huo YR, Eslick GD (2015) Microwave ablation compared to radiofrequency ablation for hepatic lesions: a meta-analysis. J Vasc Interv Radiol 26:1139–1146.e2CrossRef
11.
Zurück zum Zitat Yu J, Yu X‑L, Han Z‑Y, Cheng Z‑G, Liu F‑Y, Zhai H‑Y et al (2017) Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut 66:1172–1173CrossRef Yu J, Yu X‑L, Han Z‑Y, Cheng Z‑G, Liu F‑Y, Zhai H‑Y et al (2017) Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut 66:1172–1173CrossRef
12.
Zurück zum Zitat Vietti Violi N, Duran R, Guiu B, Cercueil J‑P, Aubé C, Digklia A et al (2018) Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol 3:317–325CrossRef Vietti Violi N, Duran R, Guiu B, Cercueil J‑P, Aubé C, Digklia A et al (2018) Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol 3:317–325CrossRef
13.
Zurück zum Zitat Kamal A, Elmoety AAA, Rostom YAM, Shater MS, Lashen SA (2019) Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial. J Gastrointest Oncol 10:562–571CrossRef Kamal A, Elmoety AAA, Rostom YAM, Shater MS, Lashen SA (2019) Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial. J Gastrointest Oncol 10:562–571CrossRef
14.
Zurück zum Zitat Peng Z‑W, Zhang Y‑J, Chen M‑S, Xu L, Liang H‑H, Lin X‑J et al (2013) Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 31:426–432CrossRef Peng Z‑W, Zhang Y‑J, Chen M‑S, Xu L, Liang H‑H, Lin X‑J et al (2013) Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 31:426–432CrossRef
15.
Zurück zum Zitat Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Li W (2018) Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 24:219–224CrossRef Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Li W (2018) Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 24:219–224CrossRef
16.
Zurück zum Zitat Wang C, Wang H, Yang W, Hu K, Xie H, Hu KQ et al (2015) Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology 61:1579–1590CrossRef Wang C, Wang H, Yang W, Hu K, Xie H, Hu KQ et al (2015) Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology 61:1579–1590CrossRef
17.
Zurück zum Zitat Kim R, Kang TW, Cha DI, Song KD, Lee MW, Rhim H et al (2019) Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications. Eur Radiol 29:654–662CrossRef Kim R, Kang TW, Cha DI, Song KD, Lee MW, Rhim H et al (2019) Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications. Eur Radiol 29:654–662CrossRef
18.
Zurück zum Zitat Hinrichs JB, Shin H‑O, Kaercher D, Hasdemir D, Murray T, Kaireit T et al (2016) Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. Eur Radiol 26:3447–3455CrossRef Hinrichs JB, Shin H‑O, Kaercher D, Hasdemir D, Murray T, Kaireit T et al (2016) Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. Eur Radiol 26:3447–3455CrossRef
19.
Zurück zum Zitat Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A et al (2017) Health-related quality of life in patients with Hepatocellular carcinoma treated with initial transarterial chemoembolization. Cardiovasc Intervent Radiol 40:1–8CrossRef Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A et al (2017) Health-related quality of life in patients with Hepatocellular carcinoma treated with initial transarterial chemoembolization. Cardiovasc Intervent Radiol 40:1–8CrossRef
20.
Zurück zum Zitat Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D et al (2016) Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v28–v37CrossRef Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D et al (2016) Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v28–v37CrossRef
21.
Zurück zum Zitat Lo C‑M, Ngan H, Tso W‑K, Liu C‑L, Lam C‑M, Poon RT‑P et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRef Lo C‑M, Ngan H, Tso W‑K, Liu C‑L, Lam C‑M, Poon RT‑P et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRef
22.
Zurück zum Zitat Niessen C, Wiggermann P, Velandia C, Stroszczynski C, Pereira PL (2013) Transarterial chemoembolization—status quo in Germany. Fortschr Röntgenstr 185:1089–1094CrossRef Niessen C, Wiggermann P, Velandia C, Stroszczynski C, Pereira PL (2013) Transarterial chemoembolization—status quo in Germany. Fortschr Röntgenstr 185:1089–1094CrossRef
23.
Zurück zum Zitat Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52CrossRef Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52CrossRef
24.
Zurück zum Zitat Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C et al (2015) Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 15:465CrossRef Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C et al (2015) Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 15:465CrossRef
26.
Zurück zum Zitat Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):S20–S37CrossRef Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):S20–S37CrossRef
27.
Zurück zum Zitat Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J‑FH (2016) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 64:106–116CrossRef Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J‑FH (2016) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 64:106–116CrossRef
28.
Zurück zum Zitat Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25CrossRef Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25CrossRef
29.
Zurück zum Zitat Marquardt S, Kirstein MM, Brüning R, Zeile M, Ferrucci PF, Prevoo W et al (2018) Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 383:2168 Marquardt S, Kirstein MM, Brüning R, Zeile M, Ferrucci PF, Prevoo W et al (2018) Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 383:2168
30.
Zurück zum Zitat Kirstein MM, Marquardt S, Jedicke N, Marhenke S, Koppert W, Manns MP et al (2017) Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol 143:2113–2121CrossRef Kirstein MM, Marquardt S, Jedicke N, Marhenke S, Koppert W, Manns MP et al (2017) Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol 143:2113–2121CrossRef
31.
Zurück zum Zitat Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK et al (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71–81CrossRef Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK et al (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71–81CrossRef
32.
Zurück zum Zitat Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA et al (2018) Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 287:1050–1058CrossRef Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA et al (2018) Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 287:1050–1058CrossRef
34.
Zurück zum Zitat Kudo M (2018) Proposal of primary endpoints for TACE combination trials with systemic therapy: lessons learned from 5 negative trials and the positive TACTICS trial. Liver Cancer 7:225–234CrossRef Kudo M (2018) Proposal of primary endpoints for TACE combination trials with systemic therapy: lessons learned from 5 negative trials and the positive TACTICS trial. Liver Cancer 7:225–234CrossRef
35.
Zurück zum Zitat Kim JH, Won HJ, Shin YM, Kim KA, Kim PN (2011) Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 196:W205–W209CrossRef Kim JH, Won HJ, Shin YM, Kim KA, Kim PN (2011) Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 196:W205–W209CrossRef
36.
Zurück zum Zitat Fu Y, Yang W, Wu W, Yan K, Xing BC, Chen M‑H (2012) Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 23:642–649CrossRef Fu Y, Yang W, Wu W, Yan K, Xing BC, Chen M‑H (2012) Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 23:642–649CrossRef
37.
Zurück zum Zitat Tan W, Deng Q, Lin S, Wang Y, Xu G (2019) Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 36:264–272PubMed Tan W, Deng Q, Lin S, Wang Y, Xu G (2019) Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 36:264–272PubMed
39.
Zurück zum Zitat Ray CE, Edwards A, Smith MT, Leong S, Kondo K, Gipson M et al (2013) Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 24:1218–1226CrossRef Ray CE, Edwards A, Smith MT, Leong S, Kondo K, Gipson M et al (2013) Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 24:1218–1226CrossRef
40.
Zurück zum Zitat Boehm LM, Jayakrishnan TT, Miura JT, Zacharias AJ, Johnston FM, Turaga KK et al (2015) Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 111:213–220CrossRef Boehm LM, Jayakrishnan TT, Miura JT, Zacharias AJ, Johnston FM, Turaga KK et al (2015) Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 111:213–220CrossRef
Metadaten
Titel
Lokoregionäre und lokal ablative Therapien von Lebertumoren
verfasst von
PD Dr. med. J. B. Hinrichs
F. K. Wacker
Publikationsdatum
09.01.2020
Verlag
Springer Medizin
Erschienen in
Die Innere Medizin / Ausgabe 2/2020
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-019-00725-8

Weitere Artikel der Ausgabe 2/2020

Die Innere Medizin 2/2020 Zur Ausgabe

Kongresse des BDI

Kongresse des BDI

Passend zum Thema

ANZEIGE

Synergien nutzen gegen Tumore

Lungen- und Magentumore können dank Immuntherapien deutlich besser behandelt werden. Dennoch kommt es trotzdem weiterhin häufig zum Krankheitsprogress. Welche Therapieoptionen sich in der Zweitlinie am besten eignen, haben wir für Sie zusammengefasst.

ANZEIGE

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

In Europa haben viele Länder dem Darmkrebs mit Hilfe von Früherkennungsprogrammen den Kampf angesagt. Es gibt einen deutlichen Zusammenhang zwischen Inzidenz und Mortalität von Darmkrebs und der Zeitspanne seit Einführung von Reihenuntersuchungen.

ANZEIGE

GI-Tumore und die Rolle von Angiogenesehemmern

Content Hub

Entdecken Sie mit praxisrelevanten Patientenfällen, kompakten Studieninhalten, informativen Experteninterviews und weiteren spannenden Inhalten, wie Sie den vielseitigen Herausforderungen bei GI-Tumoren begegnen können. Hier erfahren Sie mehr! PP-RB-DE-2009